Research ExplorerPublicationsAneurysm treatment with WEB in the cumulative population of ...

Aneurysm treatment with WEB in the cumulative population of two prospective, multicenter series: 3-year follow-up

Standard

Aneurysm treatment with WEB in the cumulative population of two prospective, multicenter series: 3-year follow-up. / Pierot, Laurent; Szikora, Istvan; Barreau, Xavier; Holtmannspoetter, Markus; Spelle, Laurent; Herbreteau, Denis; Fiehler, Jens; Costalat, Vincent; Klisch, Joachim; Januel, Anne-Christine; Weber, Werner; Liebig, Thomas; Stockx, Luc; Berkefeld, Joachim; Moret, Jacques; Molyneux, Andy; Byrne, James.

In: J NEUROINTERV SURG, Vol. 13, No. 4, 04.2021, p. 363-368.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Pierot, L, Szikora, I, Barreau, X, Holtmannspoetter, M, Spelle, L, Herbreteau, D, Fiehler, J, Costalat, V, Klisch, J, Januel, A-C, Weber, W, Liebig, T, Stockx, L, Berkefeld, J, Moret, J, Molyneux, A & Byrne, J 2021, 'Aneurysm treatment with WEB in the cumulative population of two prospective, multicenter series: 3-year follow-up', J NEUROINTERV SURG, vol. 13, no. 4, pp. 363-368. https://doi.org/10.1136/neurintsurg-2020-016151

APA

Pierot, L., Szikora, I., Barreau, X., Holtmannspoetter, M., Spelle, L., Herbreteau, D., Fiehler, J., Costalat, V., Klisch, J., Januel, A-C., Weber, W., Liebig, T., Stockx, L., Berkefeld, J., Moret, J., Molyneux, A., & Byrne, J. (2021). Aneurysm treatment with WEB in the cumulative population of two prospective, multicenter series: 3-year follow-up. J NEUROINTERV SURG, 13(4), 363-368. https://doi.org/10.1136/neurintsurg-2020-016151

Vancouver

Pierot L, Szikora I, Barreau X, Holtmannspoetter M, Spelle L, Herbreteau D et al. Aneurysm treatment with WEB in the cumulative population of two prospective, multicenter series: 3-year follow-up. J NEUROINTERV SURG. 2021 Apr;13(4):363-368. https://doi.org/10.1136/neurintsurg-2020-016151

Bibtex

@article{11fc0931a1d849afbacd160c0c592c86,
title = "Aneurysm treatment with WEB in the cumulative population of two prospective, multicenter series: 3-year follow-up",
abstract = "BACKGROUND: WEB treatment is an endovascular approach for wide-neck bifurcation aneurysms that has demonstrated high safety and good efficacy in mid-term follow-up. While evaluating safety in the long term is important to determine if delayed adverse events occur affecting late morbidity and mortality, the most important point to evaluate is the long-term stability of aneurysm occlusion. The current analysis reports the 3-year clinical and anatomical results of WEB treatment in the combined population of two European trials (WEBCAST (WEB Clinical Assessment of Intrasaccular Aneurysm Therapy) and WEBCAST-2).METHODS: Aneurysm occlusion was evaluated using a 3-grade scale: complete occlusion, neck remnant, and aneurysm remnant.RESULTS: The safety population comprised 79 patients. The efficacy population comprised 61 aneurysms. Aneurysm locations were middle cerebral artery in 32/61 aneurysms (52.5%), anterior communicating artery in 13/61 (21.3%), basilar artery in 9/61 (14.8%), and internal carotid artery terminus in 7/61 (11.5%). No adverse events related to the device or procedure occurred between 2 and 3 years. At 3 years, complete occlusion was observed in 31/61 (50.8%) aneurysms, neck remnant in 20/61 (32.8%), and aneurysm remnant in 10/61 (16.4%). Between 1 year and 3 years, aneurysm occlusion was improved or stable in 53/61 (86.9%) aneurysms and worsened in 8/61 (13.1%). Worsening was mostly from complete occlusion to neck remnant in 6/61 (9.8%) aneurysms. The retreatment rate at 3 years was 11.4%.CONCLUSIONS: This analysis confirms the high safety profile of WEB. Moreover, evidence demonstrates the great stability of aneurysm occlusion with adequate occlusion (complete occlusion or neck remnant) in 83.6% of aneurysms.CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. WEBCAST and WEBCAST-2: Unique identifier: NCT01778322.",
author = "Laurent Pierot and Istvan Szikora and Xavier Barreau and Markus Holtmannspoetter and Laurent Spelle and Denis Herbreteau and Jens Fiehler and Vincent Costalat and Joachim Klisch and Anne-Christine Januel and Werner Weber and Thomas Liebig and Luc Stockx and Joachim Berkefeld and Jacques Moret and Andy Molyneux and James Byrne",
note = "{\textcopyright} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2021",
month = apr,
doi = "10.1136/neurintsurg-2020-016151",
language = "English",
volume = "13",
pages = "363--368",
journal = "J NEUROINTERV SURG",
issn = "1759-8478",
publisher = "BMJ PUBLISHING GROUP",
number = "4",

}

RIS

TY - JOUR

T1 - Aneurysm treatment with WEB in the cumulative population of two prospective, multicenter series: 3-year follow-up

AU - Pierot, Laurent

AU - Szikora, Istvan

AU - Barreau, Xavier

AU - Holtmannspoetter, Markus

AU - Spelle, Laurent

AU - Herbreteau, Denis

AU - Fiehler, Jens

AU - Costalat, Vincent

AU - Klisch, Joachim

AU - Januel, Anne-Christine

AU - Weber, Werner

AU - Liebig, Thomas

AU - Stockx, Luc

AU - Berkefeld, Joachim

AU - Moret, Jacques

AU - Molyneux, Andy

AU - Byrne, James

N1 - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2021/4

Y1 - 2021/4

N2 - BACKGROUND: WEB treatment is an endovascular approach for wide-neck bifurcation aneurysms that has demonstrated high safety and good efficacy in mid-term follow-up. While evaluating safety in the long term is important to determine if delayed adverse events occur affecting late morbidity and mortality, the most important point to evaluate is the long-term stability of aneurysm occlusion. The current analysis reports the 3-year clinical and anatomical results of WEB treatment in the combined population of two European trials (WEBCAST (WEB Clinical Assessment of Intrasaccular Aneurysm Therapy) and WEBCAST-2).METHODS: Aneurysm occlusion was evaluated using a 3-grade scale: complete occlusion, neck remnant, and aneurysm remnant.RESULTS: The safety population comprised 79 patients. The efficacy population comprised 61 aneurysms. Aneurysm locations were middle cerebral artery in 32/61 aneurysms (52.5%), anterior communicating artery in 13/61 (21.3%), basilar artery in 9/61 (14.8%), and internal carotid artery terminus in 7/61 (11.5%). No adverse events related to the device or procedure occurred between 2 and 3 years. At 3 years, complete occlusion was observed in 31/61 (50.8%) aneurysms, neck remnant in 20/61 (32.8%), and aneurysm remnant in 10/61 (16.4%). Between 1 year and 3 years, aneurysm occlusion was improved or stable in 53/61 (86.9%) aneurysms and worsened in 8/61 (13.1%). Worsening was mostly from complete occlusion to neck remnant in 6/61 (9.8%) aneurysms. The retreatment rate at 3 years was 11.4%.CONCLUSIONS: This analysis confirms the high safety profile of WEB. Moreover, evidence demonstrates the great stability of aneurysm occlusion with adequate occlusion (complete occlusion or neck remnant) in 83.6% of aneurysms.CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. WEBCAST and WEBCAST-2: Unique identifier: NCT01778322.

AB - BACKGROUND: WEB treatment is an endovascular approach for wide-neck bifurcation aneurysms that has demonstrated high safety and good efficacy in mid-term follow-up. While evaluating safety in the long term is important to determine if delayed adverse events occur affecting late morbidity and mortality, the most important point to evaluate is the long-term stability of aneurysm occlusion. The current analysis reports the 3-year clinical and anatomical results of WEB treatment in the combined population of two European trials (WEBCAST (WEB Clinical Assessment of Intrasaccular Aneurysm Therapy) and WEBCAST-2).METHODS: Aneurysm occlusion was evaluated using a 3-grade scale: complete occlusion, neck remnant, and aneurysm remnant.RESULTS: The safety population comprised 79 patients. The efficacy population comprised 61 aneurysms. Aneurysm locations were middle cerebral artery in 32/61 aneurysms (52.5%), anterior communicating artery in 13/61 (21.3%), basilar artery in 9/61 (14.8%), and internal carotid artery terminus in 7/61 (11.5%). No adverse events related to the device or procedure occurred between 2 and 3 years. At 3 years, complete occlusion was observed in 31/61 (50.8%) aneurysms, neck remnant in 20/61 (32.8%), and aneurysm remnant in 10/61 (16.4%). Between 1 year and 3 years, aneurysm occlusion was improved or stable in 53/61 (86.9%) aneurysms and worsened in 8/61 (13.1%). Worsening was mostly from complete occlusion to neck remnant in 6/61 (9.8%) aneurysms. The retreatment rate at 3 years was 11.4%.CONCLUSIONS: This analysis confirms the high safety profile of WEB. Moreover, evidence demonstrates the great stability of aneurysm occlusion with adequate occlusion (complete occlusion or neck remnant) in 83.6% of aneurysms.CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. WEBCAST and WEBCAST-2: Unique identifier: NCT01778322.

U2 - 10.1136/neurintsurg-2020-016151

DO - 10.1136/neurintsurg-2020-016151

M3 - SCORING: Journal article

C2 - 32532858

VL - 13

SP - 363

EP - 368

JO - J NEUROINTERV SURG

JF - J NEUROINTERV SURG

SN - 1759-8478

IS - 4

ER -